Public Policy

Republican Budget and Policy Battles Reshape US Healthcare
Public Policy Republican Budget and Policy Battles Reshape US Healthcare

The shifting landscape of American health policy is currently defined by a high-stakes tension between federal legislative timelines and immediate state-level anxieties. As the 2025 budget bill looms over the healthcare system, the ripple effects are already being felt in communities where Medicaid

Are Joint Ventures Reshaping Private Equity in Healthcare?
Public Policy Are Joint Ventures Reshaping Private Equity in Healthcare?

The healthcare landscape is shifting beneath our feet, moving away from traditional buyouts toward more complex, often invisible financial arrangements. To help us navigate these changes, we are joined by Faisal Zain, a seasoned healthcare expert who has spent years at the intersection of medical

NHS Warns Staff That Snooping Into Patient Records Is a Crime
Public Policy NHS Warns Staff That Snooping Into Patient Records Is a Crime

Maintaining the confidentiality of medical records is a cornerstone of modern healthcare, yet the temptation for staff to snoop into the private lives of patients remains a significant challenge for the National Health Service. The organization recently issued a series of blunt warnings to its vast

New Medicaid Work Rules Threaten US Farmworker Healthcare
Public Policy New Medicaid Work Rules Threaten US Farmworker Healthcare

Across the sprawling agricultural heartlands of the United States, a quiet but profound transformation in federal healthcare policy is currently jeopardizing the physical well-being of the very individuals who ensure the nation's tables remain full. Implementation of the One Big Beautiful Bill

Can New Laws Protect Physician Autonomy From Corporations?
Public Policy Can New Laws Protect Physician Autonomy From Corporations?

The rapid consolidation of medical practices under private equity umbrellas has fundamentally altered the traditional landscape of American healthcare delivery, sparking a fierce regulatory response across several states. Historically, the Corporate Practice of Medicine doctrine was established to

FDA Streamlines Phase 3 Path for Alterity’s MSA Drug
Public Policy FDA Streamlines Phase 3 Path for Alterity’s MSA Drug

The diagnostic journey for patients battling Multiple System Atrophy remains one of the most daunting challenges in modern neurology due to the rapid progression of symptoms and the lack of disease-modifying therapies. Alterity Therapeutics recently achieved a major regulatory milestone that could

Loading

Subscribe to our weekly news digest

Keep up to date with the latest news and events

Paperplanes Paperplanes Paperplanes
Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later